Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, By Cause (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Type (Diagnosis and Treatment), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific) Industry Trends and Forecast to 2029.
Market Analysis and Insights: Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market
Asia-Pacific acute respiratory distress syndrome (ARDS) market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 11.1% in the forecast period of 2022 to 2029 and is expected to reach USD 4,165.51 million by 2029. Increasing prevalence of COVID-19 act as driver for the acute respiratory distress syndrome (ARDS) market growth.
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that allows fluid to leak into the lungs. Most people who get ARDS are already at the hospital for trauma or illness like COVID-19. The syndrome usually occurs when fluids build up in the tiny, elastic air sacs called alveoli in lungs. This fluid build-up causes less oxygen reach the bloodstream. This deprives the organs to get enough oxygen for their normal function. People with other illness develops ARDS within few hours to days after the precipitating injury or infection. The risk of death increases with age and depending on severity of illness patients surviving the syndrome becomes hard. Severe illness or injury which causing damage to the membrane sacs of lungs leads to ARDS. The most common underlying causes for the said diseases includes sepsis, inhalation of harmful substances, severe pneumonia, head, chest or other major injury, coronavirus disease 2019 (COVID-19) and others.
Increasing prevalence and incidence of acute lung injury, wide range of risk factors for ARDS and acceleration in patient pool of COVID-19 with ARDS acts as driver for the acute respiratory distress syndrome (ARDS) market. The other factors which are anticipated to propel the growth of the Asia-Pacific acute respiratory distress syndrome (ARDS) market include the rising rate of air pollution and life style related diseases and Increasing accident rates and trauma causing ARDS.
However, the factors such as the complications associated with treatments, high cost of devices and treatments are hampering the growth of the Asia-Pacific acute respiratory distress syndrome (ARDS) market. On the other hand, the growing geriatric population, rising healthcare expenditure and strategic Initiatives by market players act as an opportunity for the growth of the Asia-Pacific acute respiratory distress syndrome (ARDS) market. The stringent Regulations for approval and multiple challenges faced by ICU nurses is the key market challenge faced in the Asia-Pacific acute respiratory distress syndrome (ARDS) market.
The acute respiratory distress syndrome (ARDS) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the acute respiratory distress syndrome (ARDS) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Acute Respiratory Distress Syndrome (ARDS) Market Scope and Market Size
The acute respiratory distress syndrome (ARDS) market is segmented on basis of cause, type, route of administration, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of cause, the Asia-Pacific acute respiratory distress syndrome (ARDS) market is segmented into coronavirus disease 2019 (COVID-19), sepsis, inhalation of harmful substances, severe pneumonia and others. In 2022, coronavirus disease 2019 (COVID-19) segment is expected to dominate the market as the number of cases in the region was high since its origination in China.
- On the basis of type, the Asia-Pacific acute respiratory distress syndrome (ARDS) market is segmented into diagnosis and treatment. In 2022, diagnosis segment is expected to dominate the market due to increasing number of hospital and diagnostic facilities to provide timely treatments.
- On the basis of route of administration, the Asia-Pacific acute respiratory distress syndrome (ARDS) market is segmented into oral, parenteral and others. The parenteral segment is further segmented into intramuscular and intravenous. In 2022, parenteral segment is expected to dominate the market due to high number of market players dealing in the segment.
- On the basis of end user, the Asia-Pacific acute respiratory distress syndrome (ARDS) market is segmented into hospitals, specialty clinics, home healthcare and others. In 2022, hospitals segment is expected to dominate the market as most people prefer hospitals for diagnosis followed by treatments.
- On the basis of distribution channel, the Asia-Pacific acute respiratory distress syndrome (ARDS) market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2022, direct tender segment is expected to dominate the market due to the fair price of products sold by manufacturers.
Acute Respiratory Distress Syndrome (ARDS) Market Country Level Analysis
The acute respiratory distress syndrome (ARDS) market is analyzed and market size information is provided by the country, five notable segments such as cause, type, route of administration, end user and distribution channel as referenced above.
The countries covered in the acute respiratory distress syndrome (ARDS) market report are the Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific.
Parenteral segment in Japan is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of increasing technological advancement in the country. The parenteral segment in China is second dominating the market owing to increasing cases of chronic respiratory diseases and high adoption of proper diagnosis. South Korea is third leading the growth of the Asia-Pacific market and parenteral segment is dominating in this country due to increasing number of biotechnology centers and research activities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to Enhance the Awareness for Acute Respiratory Distress Syndrome (ARDS) Treatment, is Boosting the Market Growth of Acute Respiratory Distress Syndrome (ARDS) Market
The acute respiratory distress syndrome (ARDS) market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.
Competitive Landscape and Acute Respiratory Distress Syndrome (ARDS) Market Share Analysis
Acute respiratory distress syndrome (ARDS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to acute respiratory distress syndrome (ARDS) market.
Some of the major companies which are dealing in the acute respiratory distress syndrome (ARDS) are Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Besmed Health Business Corp., Armstrong Medical, Smiths Medical (part of ICU Medical, Inc.), ResMed, Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., EUROSETS and among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many contract and agreement are also initiated by the companies’ worldwide which are also accelerating the acute respiratory distress syndrome (ARDS) market.
For instance,
- In May 2021, Medtronic announced the launch of SonarMed airway monitoring system. The system utilizes acoustic technology to check for endotracheal tube obstruction. This has helped the company to increase its product portfolio.
- In July 2020, F. Hoffman-La Roche Ltd announced the launch of SARS-CoV-2 rapid antibody test. The test was launched in partnership with SD Biosenseor, Inc. This has helped the company to increase its product portfolio.
Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company footprints in the acute respiratory distress syndrome market which also provides the benefit for organization’s profit growth.
SKU-